Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
2(22%)
Results Posted
83%(5 trials)

Phase Distribution

Ph phase_3
1
11%
Ph phase_2
7
78%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
7(77.8%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Withdrawn1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 27 (77.8%)
Phase 31 (11.1%)

Trials by Status

completed667%
withdrawn111%
recruiting111%
active_not_recruiting111%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_2

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

NCT05933499
completedphase_1

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

NCT06890611
active_not_recruitingphase_2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728
withdrawnphase_2

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

NCT06901349
completedphase_2

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

NCT05616013
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05933499Phase 2

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

Recruiting
NCT06890611Phase 1

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

Completed
NCT06643728Phase 2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Active Not Recruiting
NCT06901349Phase 2

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Withdrawn
NCT05616013Phase 2

Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

Completed
NCT02333331Phase 2

Dose Range Finding Study of Bimagrumab in Sarcopenia

Completed
NCT02152761Phase 2

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Completed
NCT02468674Phase 2

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

Completed
NCT02573467Phase 3

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9